Table of Contents
<< Previous Issue | Jun 2015 (Vol: 2015, Issue: 6) | Next Issue >> |
- Section: Licensing
-
Achillion Disappoints Investors by Partnering HCV Assets with Janssen
- Section: Mergers & Acquisitions
-
Endo to Acquire Par Pharma for US$8.05 B to Become Top 5 US Generics Company
-
NantPharma to Acquire Third-Generation Paclitaxel from Sorrento Therapeutics in Potential US$1.3 B Deal
- Section: Research & Development
-
Juno Therapeutics and Editas Medicine Collaborate to Develop Next-Generation CAR-T Therapeutics Using CRISPR/Cas9